U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C28H41N3O3.ClH
Molecular Weight 504.104
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of TIROPRAMIDE HYDROCHLORIDE

SMILES

Cl.CCCN(CCC)C(=O)C(CC1=CC=C(OCCN(CC)CC)C=C1)NC(=O)C2=CC=CC=C2

InChI

InChIKey=SVCQSEFEZWMYSA-UHFFFAOYSA-N
InChI=1S/C28H41N3O3.ClH/c1-5-18-31(19-6-2)28(33)26(29-27(32)24-12-10-9-11-13-24)22-23-14-16-25(17-15-23)34-21-20-30(7-3)8-4;/h9-17,26H,5-8,18-22H2,1-4H3,(H,29,32);1H

HIDE SMILES / InChI

Molecular Formula C28H41N3O3
Molecular Weight 467.6434
Charge 0
Count
Stereochemistry RACEMIC
Additional Stereochemistry No
Defined Stereocenters 0 / 1
E/Z Centers 0
Optical Activity ( + / - )

Molecular Formula ClH
Molecular Weight 36.461
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Tiropramide is an antispasmodic medication. It acts by increasing cAMP concentration in smooth muscle possibly because of inhibition of cAMP catabolism. The drug is marketed worldwide for the treatment of irritable bowel syndrome, biliary dyskinesia, acute spasmodic dysphoric syndromes, and other urological and gynecological disorders.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
19.0 µM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
ALFOSPAS

Approved Use

Painful-spastic syndromes such as acute hepatobiliary colic, abdominal different nature, kidney or ureteral. Spasms and abdominal pain originating from gastrointestinal dyskinesia, cholelithiasis, cholecystitis, post-surgical adhesions.
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
106.76 ng/mL
100 mg single, oral
dose: 100 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
TIROPRAMIDE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
352.81 ng × h/mL
100 mg single, oral
dose: 100 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
TIROPRAMIDE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
3.07 h
100 mg single, oral
dose: 100 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
TIROPRAMIDE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
Doses

Doses

DosePopulationAdverse events​
300 mg 3 times / day multiple, oral
Highest studied dose
Dose: 300 mg, 3 times / day
Route: oral
Route: multiple
Dose: 300 mg, 3 times / day
Sources:
unhealthy, ADULT
Health Status: unhealthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
400 mg single, oral
Highest studied dose
Dose: 400 mg
Route: oral
Route: single
Dose: 400 mg
Sources:
healthy, ADULT
Health Status: healthy
Age Group: ADULT
Sex: M+F
Food Status: UNKNOWN
Sources:
PubMed

PubMed

TitleDatePubMed
Pharmacokinetics of tiropramide after single doses in man.
1986-04
Mechanism of smooth muscle relaxation by tiropramide.
1981-01
Substance Class Chemical
Created
by admin
on Mon Mar 31 19:30:18 GMT 2025
Edited
by admin
on Mon Mar 31 19:30:18 GMT 2025
Record UNII
9523013Y6R
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
ALFOSPAS
Preferred Name English
TIROPRAMIDE HYDROCHLORIDE
MART.   MI   WHO-DD  
Common Name English
TIROPRAMIDE HCL
Common Name English
TIROPRAMIDE HYDROCHLORIDE [MI]
Common Name English
TIROPRAMIDE HYDROCHLORIDE [JAN]
Common Name English
DL-.ALPHA.-BENZAMIDO-P-(2-(DIETHYLAMINO)ETHOXY)-N,N-DIPROPYLHYDROCINNAMAMIDE HYDROCHLORIDE
Common Name English
MAIORAD
Brand Name English
Tiropramide hydrochloride [WHO-DD]
Common Name English
TIROPRAMIDE HYDROCHLORIDE [MART.]
Common Name English
BENZENEPROPANAMIDE, ALPHA-(BENZOYLAMINO)-4-(2-(DIETHYLAMINO)ETHOXY)- N,N-DIPROPYL-, HYDROCHLORIDE, (±)-
Systematic Name English
Code System Code Type Description
FDA UNII
9523013Y6R
Created by admin on Mon Mar 31 19:30:18 GMT 2025 , Edited by admin on Mon Mar 31 19:30:18 GMT 2025
PRIMARY
CAS
57227-16-4
Created by admin on Mon Mar 31 19:30:18 GMT 2025 , Edited by admin on Mon Mar 31 19:30:18 GMT 2025
NON-SPECIFIC STOICHIOMETRY
EPA CompTox
DTXSID70972684
Created by admin on Mon Mar 31 19:30:18 GMT 2025 , Edited by admin on Mon Mar 31 19:30:18 GMT 2025
PRIMARY
RXCUI
236681
Created by admin on Mon Mar 31 19:30:18 GMT 2025 , Edited by admin on Mon Mar 31 19:30:18 GMT 2025
PRIMARY RxNorm
PUBCHEM
134448
Created by admin on Mon Mar 31 19:30:18 GMT 2025 , Edited by admin on Mon Mar 31 19:30:18 GMT 2025
PRIMARY
CAS
53567-47-8
Created by admin on Mon Mar 31 19:30:18 GMT 2025 , Edited by admin on Mon Mar 31 19:30:18 GMT 2025
PRIMARY
EVMPD
SUB15577MIG
Created by admin on Mon Mar 31 19:30:18 GMT 2025 , Edited by admin on Mon Mar 31 19:30:18 GMT 2025
PRIMARY
MERCK INDEX
m10892
Created by admin on Mon Mar 31 19:30:18 GMT 2025 , Edited by admin on Mon Mar 31 19:30:18 GMT 2025
PRIMARY Merck Index
ECHA (EC/EINECS)
260-634-0
Created by admin on Mon Mar 31 19:30:18 GMT 2025 , Edited by admin on Mon Mar 31 19:30:18 GMT 2025
PRIMARY
SMS_ID
100000091756
Created by admin on Mon Mar 31 19:30:18 GMT 2025 , Edited by admin on Mon Mar 31 19:30:18 GMT 2025
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY